technology

Precision medicine with neuron specific targeting
using non-invasive brain delivery technology

The challenge of delivering oligonucleotides
to the central nervous system (CNS)

  • Reaching the CSF is only the first challenge – in order to serve as a effective therapy the oligonucleotide should be target the right brain nucleolus
  • Out of about 1.7B cells in the brain roughly 50% are neurons
  • 350,000 serotonergic neurons are 0.02% of the cells in the brain – a very small target

Our technology enables targeted delivery to specific neuronal populations

  • miCure’s technology allows to conjugate small molecules to microRNAs for cell specific delivery in the brain

  • The small molecule component binds to a specific neurotransmitter transporter located in the cellular surface of the neuron and promotes the selective delivery of the therapeutic microRNA
technology-4
  • TPH2+ cells

  • A488-MIC-083

  • DAPI nucleous

Selective accumulation of MIC-083 in tryptophan hydroxylase2-positive (TPH2-positive) 5-hydroxytryptamine (5-HT) neurons after intranasal administration.